Table 2.

Analysis of primary outcome: CDI recurrence within 12 weeks

	Placebo (n=74)	Rifaximin (n=77)	Risk difference (95% CI, p values)
Main analysis: available case
Primary outcome data available	61	69
No recurrence	43 (70.5%)	58 (84.1%)
Recurrence	18 (29.5%)	11 (15.9%)	−13.7% (−28.1% to 0.7%, p=0.06)

Number of participants with primary outcome data available is used as the denominator for CDI recurrence.

Risk difference/risk ratio and 95% CIs calculated using generalised estimating equations (with an exchangeable correlation matrix to account for hospital) using the Binomial family.

CDI, Clostridium difficile infection.